The Wilms' tumor suppressor WT1 enhances CD95L expression and promotes activation-induced cell death in leukemic T cells

International Journal of Cancer

Volumn 134, Issue 2, 2014, Pages 291-300

  Bourkoula, Konstantina ^a   Englert, Christoph ^b   Giaisi, Marco ^a   Köhler, Rebecca ^a   Krammer, Peter H ^a   Li Weber, Min ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

apoptosis; CD95 ligand; leukemia; transcriptional regulation; WT1

Indexed keywords

CD19 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; LUCIFERASE; MICROSOMAL AMINOPEPTIDASE; SMALL INTERFERING RNA; T LYMPHOCYTE RECEPTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WILMS TUMOR SUPPRESSOR 1;

ARTICLE; BINDING SITE; CANCER CELL; CELL DEATH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE;

APOPTOSIS; CD95 LIGAND; LEUKEMIA; TRANSCRIPTIONAL REGULATION; WT1;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FAS LIGAND PROTEIN; HUMANS; LEUKEMIA, T-CELL; LYMPHOCYTE ACTIVATION; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; WT1 PROTEINS;

EID: 84887475499     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28379     Document Type: Article

References (50)

1. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-20.
2. Huff V,. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 2011; 11: 111-21.
3. Scharnhorst V, van der Eb AJ, Jochemsen AG,. WT1 proteins: functions in growth and differentiation. Gene 2001; 273: 141-61. (Pubitemid 32786908)
4. Hastie ND,. Life, sex, and WT1 isoformsthree amino acids can make all the difference. Cell 2001; 106: 391-4. (Pubitemid 32786981)
5. Bruening W, Pelletier J,. A non-AUG translational initiation event generates novel WT1 isoforms. J Biol Chem 1996; 271: 8646-54. (Pubitemid 26123279)
6. Scharnhorst V, Dekker P, van der Eb AJ, et al. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties. J Biol Chem 1999; 274: 23456-62.
7. Larsson SH, Charlieu JP, Miyagawa K, et al. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 1995; 81: 391-401.
8. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-9. (Pubitemid 24328100)
9. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405-12. (Pubitemid 27080005)
10. Barragán E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004; 89: 926-33. (Pubitemid 39049900)
11. Saglio G, Carturan S, Grillo S, et al. WT1 overexpression: a clinically useful marker in acute and chronic myeloid leukemias. Hematology 2005; 1: 76-8. (Pubitemid 41825696)
12. Boublikova L, Kalinova M, Ryan J, et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006; 20: 254-63. (Pubitemid 43148663)
13. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060-7.
14. Pritchard-Jones K, Renshaw J, King-Underwood L,. The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient. Hum Mol Genet 1994; 3: 1633-7. (Pubitemid 24295461)
15. King-Underwood L, Renshaw J, Pritchard-Jones K,. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 1996; 87: 2171-9.
16. Miyagawa K, Hayashi Y, Fukuda T, et al. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. Genes Chromosomes Cancer 1999; 25: 176-83. (Pubitemid 29226601)
17. Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26: 5429-35.
18. Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in T-ALL. Blood 2009; 114: 1038-45.
19. Renneville A, Kaltenbach S, Clappier E, et al. Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies. Leukemia 2010; 24: 476-80.
20. Kerst G, Bergold N, Gieseke F, et al. WT1 protein expression in childhood acute leukemia. Am J Hematol 2008; 83: 382-6. (Pubitemid 351614751)
21. Krammer PH, Arnold R, Lavrik IN,. Life and death in peripheral T cells. Nat Rev Immunol 2007; 7: 532-42. (Pubitemid 46987784)
22. Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181: 71-7.
23. Brenner D, Krammer PH, Arnold R,. Concepts of activated T cell death. Crit Rev Oncol Hematol 2008; 66: 52-64.
24. Schneider U, Schwenk HU, Bornkamm G,. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 1977; 19: 621-6. (Pubitemid 8094638)
25. Gootenberg JE, Ruscetti FW, Mier JW, et al. Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med 1981; 154: 1403-18. (Pubitemid 12235188)
26. Minowada J, Onuma T, Moore GE,. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 1972; 49: 891-5.
27. Drexler HG, Gaedicke G, Minowada J,. Isoenzyme studies in human leukemia-lymphoma cell lines. I. Carboxylic esterase. Leuk Res 1985; 9: 209-29. (Pubitemid 15120430)
28. Kaltoft K, Bisballe S, Dyrberg T, et al. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol 1992; 28A: 161-7
29. Rowe T, Dezzutti C, Guenthner PC, et al. Characterization of a HTLV-I-infected cell line derived from a patient with adult T-cell leukemia with stable co-expression of CD4 and CD8. Leuk Res 1995; 19: 621-8.
30. Smith SD, Morgan R, Link MP, et al. Cytogenetic and immunophenotypic analysis of cell lines established from patients with T cell leukemia/lymphoma. Blood 1986; 67: 650-6. (Pubitemid 16130252)
31. Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 1988; 72: 234-40.
32. Moore GE, Mitchen JR, Woods LK,. Human cell line RPMI M7021 established from a liposarcoma. In Vitro 1973; 9: 135-8.
33. Adams RA, Flowers A, Davis BJ,. Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2. Cancer Res 1968; 28: 1121-5.
34. Englert C, Hou X, Maheswaran S, et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995; 14: 4662-75.
35. Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-9.
36. Li-Weber M, Laur O, Krammer PH,. Novel Egr/NF-AT composite sites mediate activation of the CD95 (APO-1/Fas) ligand promoter in response to T cell stimulation. Eur J Immunol 1999; 29: 3017-27. (Pubitemid 30099026)
37. Elser B, Kriz W, Bonventre JV, et al. The Krüppel-associated box (KRAB)-zinc finger protein Kid-1 and the Wilms' tumor protein WT1, two transcriptional repressor proteins, bind to heteroduplex DNA. J Biol Chem 1997; 272: 27908-12. (Pubitemid 27473594)
38. Rauscher FJ III, Morris JF, Tournay OE, et al. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 1990; 250: 1259-62. (Pubitemid 120031839)
39. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-78. (Pubitemid 24006113)
40. Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87: 2878-84. (Pubitemid 26102238)
41. Ito K, Oji Y, Tatsumi N, et al. Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 2006; 25: 4217-29. (Pubitemid 44079455)
42. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617-28. (Pubitemid 38528701)
43. Smith SI, Down M, Boyd AW, et al. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice. Cancer Res 2000; 60: 808-14. (Pubitemid 30129506)
44. Kaminski M, Kiessling M, Süss D, et al. Novel role for mitochondria: protein kinase Ctheta-dependent oxidative signaling organelles in activation-induced T-cell death. Mol Cell Biol 2007; 27: 3625-39. (Pubitemid 46726173)
45. Gülow K, Kaminski M, Darvas K, et al. HIV-1 trans-activator of transcription substitutes for oxidative signaling in activation-induced T cell death. J Immunol 2005; 174: 5249-60. (Pubitemid 40593163)
46. Lücking-Famira KM, Daniel PT, Möller P, et al. APO-1 (CD95) mediated apoptosis in human T-ALL engrafted in SCID mice. Leukemia 1994; 8: 1825-33. (Pubitemid 24363055)
47. Zhu JY, Giaisi M, Köhler R, et al. Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ 2009; 16: 1289-99.
48. Chen L, Park SM, Tumanov AV, et al. CD95 promotes tumour growth. Nature 2010; 465: 492-6.
49. Martin-Villalba A, Llorens-Bobadilla E, Wollny D,. CD95 in cancer: tool or target? Trends Mol Med 2013; 19: 329-335.
50. Paulsen M, Valentin S, Mathew B, et al. Modulation of CD4+ T-cell activation by CD95 co-stimulation. Cell Death Differ 2011; 18: 619-31.